Department of Surgery, Maastricht University Medical Centre, Maastricht, Netherlands.
Lancet Oncol. 2010 Sep;11(9):835-44. doi: 10.1016/S1470-2045(10)70172-8. Epub 2010 Aug 6.
Locally advanced rectal cancer is usually treated with preoperative chemoradiation. After chemoradiation and surgery, 15-27% of the patients have no residual viable tumour at pathological examination, a pathological complete response (pCR). This study established whether patients with pCR have better long-term outcome than do those without pCR.
In PubMed, Medline, and Embase we identified 27 articles, based on 17 different datasets, for long-term outcome of patients with and without pCR. 14 investigators agreed to provide individual patient data. All patients underwent chemoradiation and total mesorectal excision. Primary outcome was 5-year disease-free survival. Kaplan-Meier survival functions were computed and hazard ratios (HRs) calculated, with the Cox proportional hazards model. Subgroup analyses were done to test for effect modification by other predicting factors. Interstudy heterogeneity was assessed for disease-free survival and overall survival with forest plots and the Q test.
484 of 3105 included patients had a pCR. Median follow-up for all patients was 48 months (range 0-277). 5-year crude disease-free survival was 83.3% (95% CI 78.8-87.0) for patients with pCR (61/419 patients had disease recurrence) and 65.6% (63.6-68.0) for those without pCR (747/2263; HR 0.44, 95% CI 0.34-0.57; p<0.0001). The Q test and forest plots did not suggest significant interstudy variation. The adjusted HR for pCR for failure was 0.54 (95% CI 0.40-0.73), indicating that patients with pCR had a significantly increased probability of disease-free survival. The adjusted HR for disease-free survival for administration of adjuvant chemotherapy was 0.91 (95% CI 0.73-1.12). The effect of pCR on disease-free survival was not modified by other prognostic factors.
Patients with pCR after chemoradiation have better long-term outcome than do those without pCR. pCR might be indicative of a prognostically favourable biological tumour profile with less propensity for local or distant recurrence and improved survival.
None.
局部晚期直肠癌通常采用术前放化疗治疗。放化疗及手术后,15-27%的患者病理检查无残留存活肿瘤,即病理完全缓解(pCR)。本研究旨在确定病理完全缓解的患者是否比无病理完全缓解的患者具有更好的长期预后。
我们在 PubMed、Medline 和 Embase 中检索了 27 篇文章,这些文章基于 17 个不同的数据集,研究了有和无 pCR 的患者的长期预后。14 名研究人员同意提供个体患者数据。所有患者均接受放化疗和全直肠系膜切除术。主要结局是 5 年无病生存率。计算 Kaplan-Meier 生存函数,并使用 Cox 比例风险模型计算危险比(HR)。进行亚组分析,以测试其他预测因素对无病生存和总生存的影响修饰。使用森林图和 Q 检验评估无病生存和总生存的异质性。
在纳入的 3105 名患者中,有 484 名患者达到 pCR。所有患者的中位随访时间为 48 个月(范围 0-277)。pCR 患者的 5 年粗无病生存率为 83.3%(95%CI 78.8-87.0)(61/419 例患者疾病复发),无 pCR 患者为 65.6%(63.6-68.0)(747/2263;HR 0.44,95%CI 0.34-0.57;p<0.0001)。Q 检验和森林图并未提示存在显著的异质性。pCR 患者的调整后无复发生存的 HR 为 0.54(95%CI 0.40-0.73),表明 pCR 患者无病生存率显著提高。调整后辅助化疗对无病生存的 HR 为 0.91(95%CI 0.73-1.12)。pCR 对无病生存的影响不受其他预后因素的影响。
放化疗后达到 pCR 的患者比未达到 pCR 的患者具有更好的长期预后。pCR 可能表明肿瘤具有预后良好的生物学特征,局部或远处复发的倾向性较低,生存改善。
无。